IGF1-LR3 (1mg)

Product Overview

IGF1-LR3 is a synthetic, modified analog of human insulin-like growth factor 1 (IGF-1). The modification includes a substitution of glutamic acid with arginine at the third position (E3R) and a 13-amino acid N-terminal extension peptide derived from methionyl porcine growth hormone. These structural changes significantly reduce binding affinity to IGF-binding proteins (IGFBPs), resulting in enhanced bioavailability compared to native IGF-1.

Specifications

• Quantity: 1mg lyophilized powder
• Purity: ≥98% (HPLC verified)
• Manufacturing: Produced in a GMP-compliant facility in the USA
• Molecular Weight: ~9,111 Da
• Amino Acids: 83 residues
• Appearance: White lyophilized powder
• Solubility: Soluble in water and dilute acetic acid (0.1%)

Storage & Handling

• Store at -20°C for long-term storage
• Stable at 2-8°C for up to 14 days after reconstitution
• Avoid repeated freeze-thaw cycles
• Reconstitute with bacteriostatic water or 0.1% acetic acid

Mechanism of Action

IGF1-LR3 binds to the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase. Receptor activation triggers autophosphorylation and subsequent recruitment of insulin receptor substrate (IRS) proteins, activating two primary downstream cascades: the PI3K/Akt/mTOR pathway (regulating protein synthesis and cellular proliferation) and the Ras/MAPK pathway (mediating cellular differentiation and gene expression). The reduced IGFBP binding of the LR3 variant extends its circulating half-life and increases receptor occupancy relative to endogenous IGF-1.

For Laboratory Use Only. Laboratory Use Only.

Quality Assurance: Each lot undergoes independent third-party LCMS/MS analysis. Certificates of Analysis are available on the product page.